Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Multiple Sclerosis

  Free Subscription

Articles published in J Neurol Sci

Retrieve available abstracts of 48 articles:
HTML format

Single Articles

    December 2022
  1. XIAN C, Barbi C, Goldsworthy MR, Venturelli M, et al
    The interaction between metaplastic neuromodulation and fatigue in multiple sclerosis.
    J Neurol Sci. 2022;444:120521.
    PubMed     Abstract available

  2. ETEMADIFAR M, Abhari AP, Nouri H, Eighani N, et al
    Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
    J Neurol Sci. 2022;444:120518.
    PubMed     Abstract available

    November 2022
  3. ABDELRAZEK MA, Tummala S, Khalid F, Tauhid S, et al
    Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    J Neurol Sci. 2022;444:120501.
    PubMed     Abstract available

    October 2022
  4. SHARMA K, Tolaymat S, Yu H, Elkhooly M, et al
    Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
    J Neurol Sci. 2022;443:120459.
    PubMed     Abstract available

    September 2022
  5. MAHLER JV, Silva GD
    Letter to the editor: Should we stop using post-contrast sequences in the follow-up MRI of patients with multiple sclerosis?
    J Neurol Sci. 2022;442:120421.

  6. GENTILI L, Capuano R, Gaetani L, Fiacca A, et al
    Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents.
    J Neurol Sci. 2022;442:120422.

  7. GROVE CR, Wagner A, Loyd BJ, Dibble LE, et al
    Unique compensatory oculomotor behavior in people living with multiple sclerosis.
    J Neurol Sci. 2022;442:120411.
    PubMed     Abstract available

    August 2022
  8. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Hagman S, et al
    Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study.
    J Neurol Sci. 2022;442:120395.
    PubMed     Abstract available

  9. MERMELSTEIN M, Naftali J, Wilf-Yarkoni A, Lotan I, et al
    Repeated lumbar puncture in search of oligoclonal bands - What is the yield?
    J Neurol Sci. 2022;439:120298.
    PubMed     Abstract available

    July 2022
  10. HARIRCHIAN MH, Zahednasab H, Karampoor S
    The enigmatic role of macrophage inhibitory factor (MIF) in the pathogenesis of multiple sclerosis (MS).
    J Neurol Sci. 2022;440:120351.

  11. HJAERESEN S, Svenningsen AF
    The possible function and regulation of macrophage migration inhibitory factor (MIF) in multiple sclerosis (MS).
    J Neurol Sci. 2022;441:120352.

  12. GENTILI L, Capuano R, Gaetani L, Fiacca A, et al
    Impact of post-contrast MRI in the definition of active multiple sclerosis.
    J Neurol Sci. 2022;440:120338.
    PubMed     Abstract available

    June 2022
  13. HJAERESEN S, Sejbaek T, Axelsson M, Mortensen SK, et al
    MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis.
    J Neurol Sci. 2022;439:120320.
    PubMed     Abstract available

  14. MOCCIA M, Buonomo AR, Scotto R, Viceconte G, et al
    Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series.
    J Neurol Sci. 2022;439:120306.
    PubMed     Abstract available

    May 2022
  15. LOREFICE L, Pilotto S, Fenu G, Cimino P, et al
    Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
    J Neurol Sci. 2022;438:120292.
    PubMed     Abstract available

    February 2022
  16. KATO S, Hagiwara A, Yokoyama K, Andica C, et al
    Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.
    J Neurol Sci. 2022;436:120205.
    PubMed     Abstract available

  17. YOUNG CA, Mills R, Langdon D, Sharrack B, et al
    The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
    J Neurol Sci. 2022;436:120188.
    PubMed     Abstract available

    January 2022
  18. DREYER-ALSTER S, Menascu S, Mandel M, Shirbint E, et al
    COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
    J Neurol Sci. 2022;434:120155.
    PubMed     Abstract available

  19. CHU L, Casserly C, Rosehart H, Morrow SA, et al
    Is there a multiple sclerosis personality? Personality characteristics in newly diagnosed multiple sclerosis and association with mood and cognition.
    J Neurol Sci. 2022;434:120145.
    PubMed     Abstract available

    November 2021
  20. MENASCU S, Fattal-Valevski A, Vaknin-Dembinsky A, Milo R, et al
    Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage.
    J Neurol Sci. 2021;432:120074.
    PubMed     Abstract available

  21. KENNEY R, Liu M, Patil S, Alroughani R, et al
    Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.
    J Neurol Sci. 2021;430:118067.
    PubMed     Abstract available

    October 2021
  22. BEARD K, Sriwastava S
    Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis.
    J Neurol Sci. 2021;430:120034.

  23. BRINGELAND GH, Blaser N, Myhr KM, Vedeler CA, et al
    Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic.
    J Neurol Sci. 2021;429:117622.
    PubMed     Abstract available

  24. SCOTT TF
    Neurosarcoidosis mimicry of MS: Clues from cases with CNS tissue diagnosis.
    J Neurol Sci. 2021;429:117621.
    PubMed     Abstract available

    September 2021
  25. PLOWMAN RS, Varma H
    Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
    J Neurol Sci. 2021;428:117591.
    PubMed     Abstract available

  26. XIE JS, Jeeva-Patel T, Margolin E
    Balo's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.
    J Neurol Sci. 2021;428:117570.
    PubMed     Abstract available

  27. CRISTIANO E, Abad P, Becker J, Carra A, et al
    Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation.
    J Neurol Sci. 2021;429:118072.
    PubMed     Abstract available

    August 2021
  28. RICE DR, Kaplan TB, Hotan GC, Vogel AC, et al
    Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
    J Neurol Sci. 2021;428:117612.
    PubMed     Abstract available

    July 2021
  29. VISSER LA, Huls SPI, Uyl-de Groot CA, de Bekker-Grob EW, et al
    An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
    J Neurol Sci. 2021;428:117587.
    PubMed     Abstract available

    June 2021
  30. VAN DER HIELE K, van Gorp DAM, van Egmond EEA, Jongen PJ, et al
    Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
    J Neurol Sci. 2021;427:117561.
    PubMed     Abstract available

  31. JAKIMOVSKI D, Zivadinov R, Vaughn CB, Ozel O, et al
    Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis.
    J Neurol Sci. 2021;427:117552.
    PubMed     Abstract available

  32. WIJERATNE T, Grisold W, Carroll W
    World Brain Day 2021 campaign continue to gain the momentum; join us to stop multiple sclerosis.
    J Neurol Sci. 2021;427:117547.

  33. FUJIMORI J, Nakashima I
    Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2021;427:117528.
    PubMed     Abstract available

    May 2021
  34. TAZZA F, Lapucci C, Cellerino M, Boffa G, et al
    Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    J Neurol Sci. 2021;427:117501.
    PubMed     Abstract available

  35. DE MERCANTI SF, Signori A, Cordioli C, Signoriello E, et al
    MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    J Neurol Sci. 2021;424:117385.
    PubMed     Abstract available

    April 2021
  36. YOUNG CA, Mills R, Rog D, Sharrack B, et al
    Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
    J Neurol Sci. 2021;426:117437.
    PubMed     Abstract available

  37. ALLUM JHJ, Rust HM, Lutz N, Schouenborg C, et al
    Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.
    J Neurol Sci. 2021;425:117432.
    PubMed     Abstract available

    March 2021
  38. FERRARO D, Annovazzi P, Lanzillo R, Calabrese M, et al
    A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.
    J Neurol Sci. 2021;424:117430.
    PubMed     Abstract available

    February 2021
  39. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
    Early neuropsychological markers of cognitive involvement in multiple sclerosis.
    J Neurol Sci. 2021;423:117349.
    PubMed     Abstract available

    January 2021
  40. BOSE G, Freedman MS
    Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    J Neurol Sci. 2021;421:117324.
    PubMed     Abstract available

  41. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    PubMed     Abstract available

    December 2020
  42. WEBER J, Bernsdorff N, Robinson T, Endres D, et al
    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    J Neurol Sci. 2020;421:117289.
    PubMed     Abstract available

    October 2020
  43. VARMA-DOYLE AV, Lukiw WJ, Zhao Y, Lovera J, et al
    A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.
    J Neurol Sci. 2020 Oct 23:117202. doi: 10.1016/j.jns.2020.117202.
    PubMed     Abstract available

  44. BARREIRO-GONZALEZ A, Sanz MT, Carratala-Bosca S, Perez-Miralles F, et al
    Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
    J Neurol Sci. 2020;419:117180.
    PubMed     Abstract available

    September 2020
  45. ILARDI M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, et al
    Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.
    J Neurol Sci. 2020;419:117159.
    PubMed     Abstract available

  46. CHAUDHRY F, Bulka H, Rathnam AS, Said OM, et al
    COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    J Neurol Sci. 2020;418:117147.
    PubMed     Abstract available

    July 2020
  47. HUGHES AJ, Patel K, Fitzgerald KC, Brown A, et al
    Reliability and validity of the multiple sclerosis resiliency scale (MSRS).
    J Neurol Sci. 2020;418:116983.
    PubMed     Abstract available

    February 2020
  48. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.